As an investor and member of numerous investment platforms and communities, I see how valuable investment research can be to better understand current market situation and make more accurate investing decisions.
Precipio, Inc. (Nasdaq: PRPO) is a cancer diagnostics reference company headquartered in New Haven, Connecticut. The firm provides the latest in advanced diagnosis and personalized medicine to oncology doctors and patients. The Company's platform is designed to eradicate the problem of misdiagnosis by providing physicians access to necessary technology so they can diagnose their patients with ease. Recently, Precipio also started offering a rapid Covid-19 antibody test on the Amazon platform.
The announcement of the 20-minute antibody test on Amazon made Precipio stocks rise more than 30% in April. Actually, since Covid-19 reached a pandemic status, the company’s stocks have increased by 284.6%. Over the past year, the S&P 500 has risen 46.49% while PRPO has gained 544.12%. Worth mentioning that Precipio has a market capitalization of $81.60 million, and generates about $3.13 million in revenue each year.
The positive results so far show that PRPO can be a thriving option for investors over 2021. Precipio wasn’t profitable in the last 12 months, but the rapid growth during the pandemic over-excited the market, in addition, the company’s growth is expected to increase even more as the antibody test becomes available on Amazon.
Is it stable?
However, Precipio’s share may not be a profitable option in the long term. In the last three years, PRPO has fallen 10%, which evidences the volatility in the stock value over the times. Considering a post-covid world, the company’s shares may revert.